ATE244018T1 - Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer - Google Patents
Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimerInfo
- Publication number
- ATE244018T1 ATE244018T1 AT96903108T AT96903108T ATE244018T1 AT E244018 T1 ATE244018 T1 AT E244018T1 AT 96903108 T AT96903108 T AT 96903108T AT 96903108 T AT96903108 T AT 96903108T AT E244018 T1 ATE244018 T1 AT E244018T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- alzheimer
- disease
- receptor ligand
- aalpha5
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9426—GABA, i.e. gamma-amino-butyrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9503601.8A GB9503601D0 (en) | 1995-02-23 | 1995-02-23 | Method of treatment and method of manufacture of medicament |
| PCT/GB1996/000377 WO1996025948A1 (en) | 1995-02-23 | 1996-02-20 | PREPARATION AND USE OF A SPECIFIC GABA-Aα5 RECEPTOR LIGAND FOR TREATMENT OF ALZHEIMER'S DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE244018T1 true ATE244018T1 (de) | 2003-07-15 |
Family
ID=10770108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96903108T ATE244018T1 (de) | 1995-02-23 | 1996-02-20 | Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6426343B1 (de) |
| EP (1) | EP0810879B1 (de) |
| JP (1) | JPH11501302A (de) |
| AT (1) | ATE244018T1 (de) |
| AU (1) | AU706515B2 (de) |
| CA (1) | CA2212058C (de) |
| DE (1) | DE69628912T2 (de) |
| ES (1) | ES2201169T3 (de) |
| GB (1) | GB9503601D0 (de) |
| WO (1) | WO1996025948A1 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4672820B2 (ja) | 1997-05-08 | 2011-04-20 | メルク シャープ エンド ドーム リミテッド | ＧＡＢＡα５リガンドとしての置換１，２，４−トリアゾロ［３，４−ａ］フタラジン誘導体 |
| GB9716344D0 (en) * | 1997-08-01 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic compounds |
| BR9908155A (pt) | 1998-02-25 | 2000-10-31 | Merck Sharp & Dohme | Composto, composição farmacêutica, uso do composto, e, processo para intensificar cognição em um sujeito sofrendo de cognição diminuìda |
| GB9805561D0 (en) * | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
| GB9805557D0 (en) * | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
| GB9805559D0 (en) * | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
| GB9824897D0 (en) * | 1998-11-12 | 1999-01-06 | Merck Sharp & Dohme | Therapeutic compounds |
| EP1131102A2 (de) * | 1998-11-12 | 2001-09-12 | Merck & Co., Inc. | Kombination von inverse agonisten des gaba-a alpha-5 rezeptor subtyps und cox-2 inhibitoren, nsaid, östrogen oder vitamin e |
| EP1129094A2 (de) | 1998-11-12 | 2001-09-05 | Merck & Co., Inc. | Therapeutische polymorphe von inverse agonisten des gaba-a alpha-5 rezeptor und pamoat-formulierungen |
| CA2371219A1 (en) * | 1999-05-07 | 2000-11-16 | Neurogen Corporation | Methods for screening gaba-modulatory compounds for specified pharmacological activities |
| US6737242B1 (en) | 1999-05-07 | 2004-05-18 | Neurogen Corporation | Methods for screening GABA-modulatory compounds for specified pharmacological activities |
| GB9911804D0 (en) * | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911803D0 (en) * | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911802D0 (en) * | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| GB0028583D0 (en) | 2000-11-23 | 2001-01-10 | Merck Sharp & Dohme | Therapeutic compounds |
| US20040023952A1 (en) * | 2001-06-20 | 2004-02-05 | Leventhal Audie G. | Enhanced brain function by gaba-ergic stimulation |
| GB0128499D0 (en) * | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
| EP1928437A2 (de) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenese mittels muscarinrezeptormodulation |
| EP1940389A2 (de) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation von neurogenese durch pde-hemmung |
| EP2314289A1 (de) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2377531A2 (de) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
| EP2026813A2 (de) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5-ht-rezeptor-vermittelte neurogenese |
| ES2573733T3 (es) | 2006-05-22 | 2016-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Tratamiento farmacológico del deterioro cognitivo |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2298296A1 (de) | 2009-08-25 | 2011-03-23 | CNRS Centre National De La Recherche Scientifique | Zusammensetzung und Behandlung kognitiver Beeinträchtigungen bei Personen mit Down-Syndrom |
| US8946206B2 (en) | 2010-12-17 | 2015-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for improving cognitive function |
| ES2702848T3 (es) | 2011-02-23 | 2019-03-05 | Coeruleus Ltd | Complejos de flumazenil, composiciones que los comprenden y usos de los mismos |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| KR101743960B1 (ko) * | 2015-07-06 | 2017-06-08 | 서울대학교산학협력단 | G단백질 결합형 수용체19 작용제를 유효성분으로 함유하는 알츠하이머 질환 또는 치매를 예방, 치료 또는 지연하기 위한 약학적 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU587802B2 (en) * | 1985-03-08 | 1989-08-31 | Ferrosan A/S | Novel oxadiazolyl imidazobenzodiazepine derivatives and methods of preparing such compounds |
| FR2672602B1 (fr) * | 1991-02-12 | 1993-06-04 | Centre Nat Rech Scient | Composes derives des beta-carbolines ligands du recepteur des benzodiazepines ayant un effet agoniste inverse et antagoniste vis-a-vis des benzodiazepines et medicaments les contenant. |
| US5182290A (en) * | 1991-08-27 | 1993-01-26 | Neurogen Corporation | Certain oxazoloquinolinones; a new class of GABA brain receptor ligands |
| US5212310A (en) | 1991-12-19 | 1993-05-18 | Neurogen Corporation | Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands |
| EP1605046B1 (de) | 1992-12-10 | 2007-11-21 | Merck Sharp & Dohme Limited | Stabil transfizierte Zelllinien welche Humane GABA-A Rezeptoren mit der Untereinheitskombination Alpha-2, Beta-3 und Gamma-2 exprimieren |
-
1995
- 1995-02-23 GB GBGB9503601.8A patent/GB9503601D0/en active Pending
-
1996
- 1996-02-20 EP EP96903108A patent/EP0810879B1/de not_active Expired - Lifetime
- 1996-02-20 ES ES96903108T patent/ES2201169T3/es not_active Expired - Lifetime
- 1996-02-20 DE DE69628912T patent/DE69628912T2/de not_active Expired - Fee Related
- 1996-02-20 US US08/894,031 patent/US6426343B1/en not_active Expired - Fee Related
- 1996-02-20 AU AU47257/96A patent/AU706515B2/en not_active Ceased
- 1996-02-20 AT AT96903108T patent/ATE244018T1/de not_active IP Right Cessation
- 1996-02-20 JP JP8525484A patent/JPH11501302A/ja not_active Withdrawn
- 1996-02-20 CA CA002212058A patent/CA2212058C/en not_active Expired - Fee Related
- 1996-02-20 WO PCT/GB1996/000377 patent/WO1996025948A1/en active IP Right Grant
-
2000
- 2000-07-20 US US09/621,319 patent/US6323198B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| GB9503601D0 (en) | 1995-04-12 |
| EP0810879B1 (de) | 2003-07-02 |
| US6426343B1 (en) | 2002-07-30 |
| ES2201169T3 (es) | 2004-03-16 |
| JPH11501302A (ja) | 1999-02-02 |
| DE69628912T2 (de) | 2004-06-03 |
| US6323198B1 (en) | 2001-11-27 |
| EP0810879A1 (de) | 1997-12-10 |
| CA2212058A1 (en) | 1996-08-29 |
| AU4725796A (en) | 1996-09-11 |
| CA2212058C (en) | 2008-05-13 |
| AU706515B2 (en) | 1999-06-17 |
| WO1996025948A1 (en) | 1996-08-29 |
| DE69628912D1 (de) | 2003-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE244018T1 (de) | Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer | |
| DE59600309D1 (de) | Vorrichtung zur Behandlung von Flüssigkeiten, insbesondere von Blut | |
| EP0671920A4 (de) | Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten. | |
| DE69525473T2 (de) | Vorrichtung zur behandlung von blutgefässen | |
| DE59611411D1 (de) | Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz | |
| DE69609868D1 (de) | Neue steroidester zur behandlung von hauterkrankungen | |
| DE69528475T2 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
| DE69633717D1 (de) | Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis | |
| ATE227127T1 (de) | Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes | |
| DE69525279D1 (de) | Behandlung von Leder zum Einfärben desselben, sowie gefärbtes Leder | |
| DE69804659T2 (de) | 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss | |
| DE69509843T2 (de) | Apparat zur Behandlung z.B. von Poststücken | |
| DE69013880T2 (de) | Verfahren und Vorrichtung zur Behandlung von Absorptionssuspensionen, die Flugasche beinhalten. | |
| ATE221763T1 (de) | Die verwendung von glyceryltriacetat zur behandlung von onychomykosen | |
| DE69007486D1 (de) | Verwendung von calciumantagonisten für die behandlung von narben. | |
| DE59008012D1 (de) | Mittel zur Behandlung von Leder und Pelzen. | |
| DE69517191T2 (de) | Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels | |
| DE59607664D1 (de) | Verfahren zur Herstellung von 2,4,4,7-Tetramethyl-oct-6-en-3-on und dessen Verwendung als Riechstoff | |
| DE69014501D1 (de) | Verfahren zur Behandlung von Titanlegierung und damit hergestelltes Stück. | |
| DE59006159D1 (de) | Verwendung von macrolactonen als antiallergica. | |
| ATE305052T1 (de) | Drogen untersuchungssystem | |
| DE69008690D1 (de) | Verfahren und Vorrichtung zur Bestimmung von aeroben Bakterien. | |
| DE59103949D1 (de) | Verfahren zur Herstellung von Leder und Pelzen. | |
| DE69007028D1 (de) | Verfahren zur Herstellung von 3,4-Epoxybutyrat und Zwischenprodukte dafür. | |
| DE69711422T2 (de) | Verwendung von (r)-verapamil als medizin zur behandlung von angina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |